No, hyperparathyroidism cannot be treated with levothyroxine
Levothyroxine is a thyroid hormone replacement medication used exclusively for treating hypothyroidism, not hyperparathyroidism—these are completely separate endocrine disorders affecting different glands with different pathophysiology.
Understanding the Distinction
Hyperparathyroidism involves overactive parathyroid glands producing excessive parathyroid hormone (PTH), leading to elevated calcium levels. Levothyroxine addresses thyroid hormone deficiency and has no mechanism of action on parathyroid function 1.
Appropriate Treatment for Hyperparathyroidism
Surgery (parathyroidectomy) is the definitive treatment for primary hyperparathyroidism 2. According to the 2025 French expert consensus, surgery should be proposed when any of the following criteria are present 2:
- Proven or low-energy bone fracture or T-score <-2.5 SD on bone densitometry
- Proven renal colic, urinary lithiasis, or nephrocalcinosis
- Glomerular filtration rate <60 mL/min/1.73 m²
- 24-hour calciuria >6.25 mmol/day (250 mg/day) in women or >7.5 mmol/day (300 mg/day) in men
- Blood calcium level >10 mg/L (0.25 mmol/L) above high normal
For patients who cannot undergo surgery due to comorbidities or who refuse surgery, pharmacological options include calcimimetics or bisphosphonates—not levothyroxine 2.
Important Clinical Caveat: The Thyroid-Parathyroid Connection
One critical exception exists: Hyperparathyroidism can be unmasked when treating hypothyroidism with levothyroxine 3. In a series of 17 patients with Hashimoto's thyroiditis, primary hyperparathyroidism became clinically apparent 2 months to 30 years after initiating thyroxine therapy 3. This occurs because:
- Untreated hypothyroidism can mask coexisting hyperparathyroidism
- Levothyroxine treatment reveals the previously hidden parathyroid dysfunction
- The levothyroxine itself does not cause or treat the hyperparathyroidism
Clinical recommendation: Evaluate parathyroid function (calcium and PTH levels) in patients with Hashimoto's thyroiditis before initiating levothyroxine therapy and at intervals thereafter 3.
Impact on Diagnostic Workup
Interestingly, levothyroxine use can affect parathyroid localization studies. Patients taking levothyroxine have significantly impaired parathyroid localization with ultrasound (48.4% vs 62.2% accuracy, p<0.01), particularly for upper gland adenomas, though sestamibi scanning remains unaffected 4. This is relevant for surgical planning but does not change the fundamental treatment approach.
Secondary Hyperparathyroidism in Chronic Kidney Disease
For secondary hyperparathyroidism in chronic kidney disease, treatment cornerstones include dietary phosphate restriction, phosphate binders, correction of hypocalcemia, and vitamin D sterols—again, not levothyroxine 5. Surgical parathyroidectomy is reserved for severe cases with hypercalcemia or hyperphosphatemia that preclude medical therapy 5.